Summarized by Masters of Longevity from TechCrunch.
Report on a major Series E funding that scales an AI-driven natural products drug discovery company toward multiple human trials and development programs.
Key Takeaways
- Enveda raised $311 million in a Series E financing that values the company at $2 billion.
- The round was led by Catalio Capital Management with participation from Iconiq and other investors.
- Enveda is advancing AI-discovered natural product candidates into human testing for skin diseases and post-GLP-1 weight maintenance.
